Skip to main
ASMB

Assembly Biosciences (ASMB) Stock Forecast & Price Target

Assembly Biosciences (ASMB) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Assembly Biosciences Inc. is advancing innovative oral therapeutics aimed at treating hepatitis B virus (HBV) infection, with a focus on improving cure rates through multiple drug candidates that target various stages of the HBV lifecycle. The company's commitment to developing novel core protein Allosteric Modulators positions it favorably within the biotechnology sector, with the potential for substantial revenue generation primarily from its HBV-cure program. Additionally, market interest in advancing treatments for hepatitis B has increased, suggesting a favorable outlook for Assembly's product pipeline and its estimated peak sales opportunity of nearly $4 billion in the U.S.

Bears say

Assembly Biosciences Inc. faces a negative outlook primarily due to the high likelihood of disappointing clinical outcomes for its key drug candidates, ABI-6250 and ABI-1179/5366, which could hinder their advancement in clinical trials. Despite some promising initial results regarding reductions in viral shedding in treated cohorts, these gains may not translate into long-term virologic successes, as evidenced by only 4% of the control group achieving favorable virologic responses. The reliance on the HBV cure program for revenue generation further exacerbates the risks, as any setbacks in these clinical candidates could severely impact the company’s financial stability and future growth prospects.

Assembly Biosciences (ASMB) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Assembly Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Assembly Biosciences (ASMB) Forecast

Analysts have given Assembly Biosciences (ASMB) a Buy based on their latest research and market trends.

According to 4 analysts, Assembly Biosciences (ASMB) has a Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Assembly Biosciences (ASMB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.